Photography by Matthew Cohen.

Approximately 56,770 Americans will be diagnosed with Pancreatic Cancer in 2019 alone and nearly 45,750 of them will succumb to it according to the American Cancer Society.

 

But there is hope

Dr. Daniel Von Hoff and his team at TGen have dedicated decades to Pancreatic Cancer Research. TGen has teamed up with researchers at 46 research institutions from around the world to form the Pancreatic Cancer Research Team. The PCRT is determined to develop revolutionary advances in treating the underlying genetic cause of this disease. TGen's continued dedication to Pancreatic Cancer early detection methods is why I have chosen to support this organization. Most patients die within 5 years of diagnosis because the symptoms were undetected and the diagnosis is made too late; early detection is the key to saving lives.


We must embrace the pain and burn it as fuel for our journey
— Kenji Miyazawa, Author and Poet

About Tgen

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. The TGen Foundation (non-profit that secures and stewards private support to fuel TGen’s biomedical discoveries ) is a 501(c)(3) Charitable Organization, Federal Tax ID: 33-1092191